Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography
- 1 April 1997
- journal article
- basic neurosciences-and-genetics
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 104 (4-5) , 329-339
- https://doi.org/10.1007/bf01277655
Abstract
Positron emission tomography (PET) was used in a multitracer protocol to evaluate D-amphetamine induced effects on dopamine biosynthesis rate and release in propofol anesthetized Rhesus monkeys.l-[β-11C]DOPA was used as biochemical probe to study the brain dopamine biosynthesis rate whilst dopamine release was followed by the binding displacement of the [11C]-radiolabelled dopamine receptor antagonists, raclopride and N-methylspiperone. Studies were performed with either a constant rate intravenous infusion of D-amphetamine aiming at plasma concentrations of 0.2 to 25 ng/ml or with intravenous bolus doses of 0.1 and 0.4 mg/ kg. Decreased binding of the dopamine receptor antagonists was measured in both modes of D-amphetamine administration but notably [11C]N-methylspiperone was less able to sense D-amphetamine induced release of dopamine. At plasma concentrations aimed above 1 ng/ml a levelling off of the binding of [11C]raclopride at 68 ± 8.1% of the baseline value indicated that displacement was only possible from a fraction of the binding sites. Amphetamine was observed to increase the rate constant forl-[β-11C]DOPA utilization in the brain. This was most likely due to an acutely induced subsensitivity of presynaptic dopamine receptors.l-[β-11C]DOPA and [11C]raclopride were found suitable to indicate changes in dopamine synthesis rate and release respectively using PET and can be used to mirror drug-induced changes of brain dopaminergic function.Keywords
This publication has 35 references indexed in Scilit:
- Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's diseaseAnnals of Neurology, 1997
- Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of l-[β-11C]DOPA and its metabolites for the validation of positron emission tomography studiesJournal of Pharmaceutical and Biomedical Analysis, 1995
- Estimation of regional cerebral utilization of [11C]-L-3, 4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomographyActa Neurologica Scandinavica, 1992
- Cerebral uptake and utilization of therapeutic [β-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor responseActa Neurologica Scandinavica, 1992
- Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brainSynapse, 1991
- Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET)Synapse, 1991
- Brain kinetics of L-[?-11 C]DOPA in humans studied by positron emission tomographyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Weighted Integration Method for Local Cerebral Blood Flow Measurements with Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1986
- Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronicd-amphetamine treatmentBrain Research, 1984
- Long-term amphetamine treatment attenuates or reverses the depression of neuronal activity produced by dopamine agonists in the ventral tegmental areaLife Sciences, 1984